SG170642A1 - Gpr41 and modulators thereof for the treatment of insulin-related disorders - Google Patents

Gpr41 and modulators thereof for the treatment of insulin-related disorders

Info

Publication number
SG170642A1
SG170642A1 SG200907252-1A SG2009072521A SG170642A1 SG 170642 A1 SG170642 A1 SG 170642A1 SG 2009072521 A SG2009072521 A SG 2009072521A SG 170642 A1 SG170642 A1 SG 170642A1
Authority
SG
Singapore
Prior art keywords
gpr41
compound
glycemic stabilizing
functionality
modulators
Prior art date
Application number
SG200907252-1A
Other languages
English (en)
Inventor
James N Leonard
Zhi Liang Chu
Marc A Bruce
P Douglas Boatman
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of SG170642A1 publication Critical patent/SG170642A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200907252-1A 2004-11-03 2005-11-01 Gpr41 and modulators thereof for the treatment of insulin-related disorders SG170642A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62486704P 2004-11-03 2004-11-03

Publications (1)

Publication Number Publication Date
SG170642A1 true SG170642A1 (en) 2011-05-30

Family

ID=36336982

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907252-1A SG170642A1 (en) 2004-11-03 2005-11-01 Gpr41 and modulators thereof for the treatment of insulin-related disorders

Country Status (12)

Country Link
US (1) US20080312277A1 (fr)
EP (1) EP1812080B1 (fr)
JP (2) JP5785354B2 (fr)
CN (1) CN101084018B (fr)
AU (1) AU2005305083B2 (fr)
CA (1) CA2584224A1 (fr)
ES (1) ES2498972T3 (fr)
HK (1) HK1100358A1 (fr)
IL (1) IL182574A (fr)
SG (1) SG170642A1 (fr)
TW (1) TWI440460B (fr)
WO (1) WO2006052566A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2014011926A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
JP6895378B2 (ja) 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
EP3939965A1 (fr) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique pour une utilisation dans des troubles associés au récepteur de s1p1
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112399874B (zh) 2018-07-13 2024-03-22 吉利德科学公司 Pd-1/pd-l1抑制剂
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232132A1 (en) * 2000-02-18 2001-08-27 Glaxo Group Limited Novel assay
EP1360199A2 (fr) * 2001-02-16 2003-11-12 Genentech, Inc. Traitement faisant appel a dkk-1 ou aux antagonistes de dkk-1
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
JP4294497B2 (ja) * 2002-04-16 2009-07-15 協和発酵キリン株式会社 内分泌系細胞株とその利用法
US7553867B2 (en) * 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2004038421A2 (fr) * 2002-10-25 2004-05-06 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)

Also Published As

Publication number Publication date
ES2498972T3 (es) 2014-09-26
CN101084018B (zh) 2013-12-18
TWI440460B (zh) 2014-06-11
EP1812080A2 (fr) 2007-08-01
JP2013082748A (ja) 2013-05-09
WO2006052566A3 (fr) 2006-10-12
WO2006052566A2 (fr) 2006-05-18
JP2008518635A (ja) 2008-06-05
EP1812080B1 (fr) 2014-07-09
US20080312277A1 (en) 2008-12-18
TW200633707A (en) 2006-10-01
AU2005305083B2 (en) 2012-02-02
JP5785354B2 (ja) 2015-09-30
IL182574A0 (en) 2008-04-13
CA2584224A1 (fr) 2006-05-18
HK1100358A1 (en) 2007-09-21
IL182574A (en) 2014-04-30
CN101084018A (zh) 2007-12-05
AU2005305083A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
SG170642A1 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
WO2008115518A3 (fr) Biomarqueurs de l'activité sirtuine et procédés d'utilisation de ceux-ci
AU2004298540A1 (en) Reagent for detecting an analyte
WO2006069399A3 (fr) Technique a modulation multiple a utiliser dans un systeme de communication
WO2006019583A3 (fr) Changements de bandes pour chaussures
EP1704817A3 (fr) Procédé et appareil pour déterminer stress clinique d'un patient
DK3578195T3 (da) Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
BRPI0513237A (pt) hidrolisados de proteìna para diminuição de pressão sanguìnea
WO2006034414A3 (fr) Analogues de loxapine et methodes d'utilisation
SG155896A1 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
BR112013003185A2 (pt) palmilhada acolchoada para calçados
AR038437A1 (es) Tintura permanente del cabello en dos pasos
ATE391563T1 (de) Oberflächenmodifizierungsverfahren
WO2004043386A3 (fr) Molecules associees de preference a des lymphocytes t effecteurs et methodes d'utilisation de ces molecules
EP1534862A4 (fr) Modulateurs de rabggt et procedes d'utilisation de ceux-ci
WO2006096740A3 (fr) Appareil et procede de clonage pour le developpement de logiciels
WO2004103394A3 (fr) Procedes et compositions de regeneration nerveuse
EP2569445A4 (fr) Dosages par criblage basés sur mag et/ou abhd6 pour sélectionner des agents favorisant la sécrétion d'insuline
DE602008002889D1 (de) Ultrapassivierung von Chromlegierungen
TW200704225A (en) Method of enabling power savings when no data is being transmitted on a media logical channel
ATE366045T1 (de) Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
WO2003016917A3 (fr) Regulateurs et modulateurs de canaux sodiques
RS63104A (en) A method for determining the biological activity of defibrotide
WO2006083373A3 (fr) Methodes et compositions permettant de moduler une fonction des keratinocytes
DK1713501T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af GPR49